Mereo BioPharma

Historical price data

Mereo BioPharma is a UK-based biopharma founded in 2015 with a mission to deliver impactful therapies for rare diseases with limited treatment options. Its core strategy involves identifying, in-licensing, and developing late-stage clinical assets that have been deprioritized by larger pharmaceutical companies, leveraging deep industry relationships and a patient-centric approach. Key achievements include a foundational asset acquisition from Novartis, a transformative 2019 merger with OncoMed that secured a NASDAQ listing, and a strategic partnership with Ultragenyx for its lead osteogenesis imperfecta program.

A strategic and operational model focused on the identification, due diligence, and development of de-risked, late-stage clinical assets deprioritized by large pharmaceutical companies, executed in a capital-efficient and patient-centric manner.

In OI, setrusumab faces limited direct competition due to its novel anabolic mechanism. In AATD-LD, alvelestat competes against established intravenous augmentation therapies and other novel mechanisms in development, differentiating itself as a direct, oral inhibitor of the destructive neutrophil elastase enzyme.